Does digoxin have a place in the treatment of the child with congenital heart disease?
The place of digoxin in the pediatric cardiologist's armamentarium remains uncertain. As an antiarrhythmic, its use in the Wolff-Parkinson-White syndrome is obsolete, but it remains useful in the treatment of the chronic atrial fibrillation seen in some patients postoperatively and in children with dilated cardiomyopathy. The efficacy of digoxin in heart failure is unproven. There is some evidence of improvement in non invasive left ventricular contractile indices in neonates and infants, but it is unclear whether this is associated with sustained clinical improvement. There is even less evidence of its effectiveness in the older child. Whilst the measurement of any effect will undoubtedly be difficult, the time has come for double-blind, placebo-controlled trials in selected groups of patients. These should be designed not only to test the notion that digoxin does not improve ventricular function, but also to embrace the possibility that its administration may result in clinical improvement over and above that following diuretics alone. An absence of proof of efficacy must be distinguished from no efficacy--more data are needed.
Redington
A N
AN
Department of Paediatric Cardiology, Brompton Hospital, London, United Kingdom.
Carvalho
J S
JS
Shinebourne
E A
EA
D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D004077:Digoxin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006330:Heart Defects, Congenital / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D007223:Infant
D004077:Digoxin